Abstract

The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-54
Application #
9858285
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Meyer, Jan-Philip; Tully, Kathryn M; Jackson, James et al. (2018) Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjug Chem 29:538-545
McFarland, Daniel C; Shaffer, Kelly; Breitbart, William et al. (2018) C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. Cancer :
Lacouture, Mario E; Anadkat, Milan; Jatoi, Aminah et al. (2018) Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 17:85-96
Blumenthal, Gideon M; Bunn Jr, Paul A; Chaft, Jamie E et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 13:1818-1831
Shaffer, Kelly M; Nelson, Christian J; DuHamel, Katherine N (2018) Barriers to participation in a sexual health intervention for men following treatment for rectal and anal cancer. Psychooncology 27:1082-1085
Park, Kay J; Patel, Prusha; Linkov, Irina et al. (2018) Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. Histopathology 72:766-776
Pianko, Matthew J; Goldberg, Aaron D; Lesokhin, Alexander M (2018) Clinical Development of PD-1 Blockade in Hematologic Malignancies. Cancer J 24:31-35
Navi, Babak B; Marshall, Randolph S; Bobrow, Dylan et al. (2018) Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial. JAMA Neurol 75:379-381
Shah, Sona; Boucai, Laura (2018) Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence. J Clin Endocrinol Metab 103:689-697
Goldman, Debra A; Hovinga, Koos; Reiner, Anne S et al. (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg :1-9

Showing the most recent 10 out of 8799 publications